April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Systemic Fluoroquinolone Antibiotic Use in Postoperative Endophthalmitis
Author Affiliations & Notes
  • J. M. Rosenthal
    Wills Eye Institute, Philadelphia, Pennsylvania
  • J. Hsu
    Retina Service,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • M. J. Spirn
    Retina Service,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • S. J. Garg
    Retina Service,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  J.M. Rosenthal, None; J. Hsu, None; M.J. Spirn, None; S.J. Garg, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3559. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. M. Rosenthal, J. Hsu, M. J. Spirn, S. J. Garg; Systemic Fluoroquinolone Antibiotic Use in Postoperative Endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3559.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To examine the effect of systemic moxifloxacin in the treatment of postoperative endophthalmitis.

Methods: : We performed a retrospective review of patients with acute postoperative endophthalmitis presenting to the Retina Service of Wills Eye Institute from February 2005 to August 2007. Patients included developed endophthalmitis within 6 weeks of cataract surgery or intraocular lens exchange and had visual acuities (VA) of hand motions or better. All underwent a vitreous or aqueous biopsy with injection of intravitreal antibiotics and received topical antibiotic drops. Patients were divided into those who either received systemic moxifloxacin (MOXI group) or did not (NO MOXI group).

Results: : 67 patients were included in the study, 35 of whom were given systemic moxifloxacin. The initial mean logMAR VA were 2.04 and 1.93 in the MOXI and NO MOXI groups, respectively. Length of follow-up ranged from 1 day to 36 months. At one week, the mean logMAR VA was 1.81 in the MOXI group and 1.92 in the NO MOXI group. At 6 weeks, the mean logMAR VA was 1.43 (approx. 20/550) and 1.61 (approx. 20/800) in the MOXI and NO MOXI groups, respectively. At six months, the mean logMAR VA was 1.13 (approx. 20/250) and 1.30 (approx. 20/400) in the MOXI and NO MOXI groups, respectively.

Keywords: antibiotics/antifungals/antiparasitics • endophthalmitis • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×